CN1646151A - 包含原花色素、用于治疗皮炎的局部用药物组合物 - Google Patents

包含原花色素、用于治疗皮炎的局部用药物组合物 Download PDF

Info

Publication number
CN1646151A
CN1646151A CNA038078589A CN03807858A CN1646151A CN 1646151 A CN1646151 A CN 1646151A CN A038078589 A CNA038078589 A CN A038078589A CN 03807858 A CN03807858 A CN 03807858A CN 1646151 A CN1646151 A CN 1646151A
Authority
CN
China
Prior art keywords
proanthocyanidin
dermatitis
pharmaceutical composition
treatment
enoxolone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA038078589A
Other languages
English (en)
Other versions
CN1646151B (zh
Inventor
M·马斯特罗多纳托
R·恰蒂尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Pharmaceutical Co Ltd
Original Assignee
Sinclair Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinclair Pharmaceuticals Ltd filed Critical Sinclair Pharmaceuticals Ltd
Publication of CN1646151A publication Critical patent/CN1646151A/zh
Application granted granted Critical
Publication of CN1646151B publication Critical patent/CN1646151B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

本发明涉及用于局部施用的药物组合物，其包含作为活性成分的单独或与甘草次酸、替美斯丁、α－红没药醇或其它具有互补活性的成分组合的原花色素与适宜的载体的混合物，可用于治疗各种疾病如特应性皮炎、变应性接触性皮炎、脂溢性皮炎、放射性皮炎、银屑病、干燥病和异位性皮炎以及治疗粘膜炎性病症。

Description

包含原花色素、用于治疗皮炎的局部用药物组合物
本发明涉及用于局部施用的药物组合物，其包含作为活性成分的原花色素、甘草次酸和替美斯丁与适宜的载体的混合物。
本发明的局部药物组合物可用于治疗皮肤的炎性病症，如特应性皮炎、变应性接触性皮炎、脂溢性皮炎、放射性皮炎、银屑病、干燥病和异位性皮炎(atopia)以及粘膜和眼的炎性病症。
皮炎是表面的皮肤炎症，其特征是水疱、红斑、水肿、渗出、剥落性或结痂损伤以及强烈的瘙痒。存在各种类型的皮炎：接触性皮炎，其可由与皮肤接触的刺激物或者由个体对其过敏的非刺激性物质导致；特应性皮炎，其是一种慢性疾病，特征是强烈的瘙痒；脂溢性皮炎，其是主要影响面部和头皮的剥落性疾病。原则上，治疗在于除去侵入物，然而该侵入物在许多情况下不能被确定或除去。因此治疗基于皮质类固醇，然而其具有熟知的副作用：它们减少免疫防御，这可诱发主要由真菌或念珠菌引起的感染；治疗的中止应该逐渐进行；它们不能在急性渗出期间使用；在停止治疗时可能出现反弹效果。此外，皮质类固醇不应用于长期治疗，特别是在儿童中，因为它们可引发全身性影响。
对于脂溢性皮炎，基于氢化植物油或亲水性矿脂的备选治疗，或者加有药物的香波(基于吡硫锌、硫化硒、硫等)不是解除性的疗法。
对于粘膜炎性病症，尤其是口、齿龈、直肠、阴道和眼粘膜的炎性病症，可使用许多局部疗法，包括使用甾族或非甾族抗炎剂，同时存在这些药物的特征性问题和副作用。
在药物和化妆品领域已经述及原花色素的不同应用。EP 0694305公开了与香豆素(七叶苷等)组合的原花色素的局部用组合物，用于治疗外周性血管病，如褥疮、瘢疤、微血管扩张(couperose)、静脉曲张等。US 5,470,874描述了用于局部使用的原花色素和维生素C的组合，作为遮光剂，以刺激胶原合成并用于修复受损的胶原。最后，JP 6,336,421涉及用于化妆品用途和抗日晒的原花色素和抗炎剂组合的局部制剂，其中在抗炎剂中引述了甘草次酸及衍生物。然而，迄今为止，原花色素在治疗疾病如慢性皮炎、脂溢性皮炎和变应性皮炎中的用途尚未述及。
原花色素广泛分布于许多植物品种中。它们是含有生物类黄酮的植物提取物，具有明确的化学谱，由约15％二聚体、约20％三聚体和四聚体以及少量儿茶素和表儿茶素组成。原花色素发挥保护皮肤免受自由基攻击的作用和通过刺激胶原生成而对皮肤结构损害发挥修复作用。它们还含有与皮肤的亲水性皮脂屏障(hydrolipidic barrier)中的必需脂肪酸类似的必需脂肪酸，这些必需脂肪酸有助于保持所述屏障的完整性。最后，原花色素可降低酶如弹性蛋白酶、胶原酶、透明质酸酶和β-葡萄醛酸糖苷酶的浓度，这些酶是破坏弹性蛋白、胶原和透明质酸蛋白的原因。因此，由于其修复、再生、营养和重建作用而恢复皮肤的弹性和张性，原花色素被广泛用于制药和化妆品工业中。
根据本发明，尤其优选从葡萄籽和葡萄(Vitis vinifera)皮提取的原花色素。最优选的是根据US 4,963,527所公开的方法制备的来自葡萄的原花色素和磷脂的复合物。
已知自光果甘草(Glycyrrhiza glabra)的根提取的18-β-甘草次酸具有对皮肤、尤其是对灼伤和充血(redness)的皮肤的抗炎性质。
替美斯丁(N-乙氧甲酰基-4-噻唑烷甲酸)发挥对抗造成皮肤损伤的氧化剂的抗游离基和保护作用，以及抑制弹性蛋白酶和胶原酶的作用。
本发明的局部用药物组合物可含有与适宜载体、优选富含多不饱和脂肪酸的载体混合的活性成分。根据本发明，适宜的载体包括角鲨烯、脂肪酸、脂肪酸酯、植物油、天然或合成的甘油三酯。更优选地，适宜的载体包括角鲨烯、烛果油、棕榈酸辛酯和月见草油。
具体地，烛果油(也称为牛油脂)是一种由饱和和不饱和脂肪的混合物组成的脂肪，其从北部非洲的一种树即牛油果(Butirospermum parkii)的种子提取，其被用于化妆品是由于其保护和软化作用，该作用使其尤其可用于敏感皮肤以及容易充血的皮肤。
月见草油(也称为夜来香油)自植物月见草(Oenothera biennis)提取，其富含皮肤和所有细胞组织再生所不可缺少的必需多不饱和脂肪酸，尤其是γ-亚麻酸。
根据优选的实施方案，本发明的药物组合物还可含有具有抗氧化活性的化合物，如生育酚和抗坏血酸或其酯，优选生育酚醋酸酯和棕榈酸抗坏血酸酯或四棕榈酸抗坏血酸酯，以进一步增强对细胞膜的保护效果和减缓多不饱和脂肪酸的氧化。
本发明的组合物可以还含有其他对治疗皮肤病具有互补或至少有用作用的活性成分。
所述活性成分的实例为：
-水杨酸，其发挥溶角蛋白作用，可用于治疗脂溢性皮炎；
-透明质酸，其由于其水合和修复作用而可用于治疗放射性皮炎；
-α-红没药醇，存在于春黄菊精油(母菊花)中的活性成分之一，其具有润泽和抗充血作用；
-吡咯烷酮羧酸锌(zinc pidolate)，其发挥轻微的收敛、润滑和润泽作用，由于其对铁离子的竞争作用而阻碍和防止自由基形成，并且在皮肤代谢的酶促过程中具有活性；
-尿囊素，其具有收敛、轻微的溶角蛋白和修复作用；
-保湿剂或润湿剂；
-羟吡酮(羟甲辛吡酮，即Octopirox)，已知具有抗皮脂溢出活性的活性剂。
因此，进一步优选的实施方案涉及用于治疗脂溢性皮炎、还含有水杨酸的本发明的药物组合物。
进一步优选的实施方案涉及用于治疗放射性皮炎、还含有透明质酸的本发明的药物组合物。
进一步优选的实施方案涉及还含有α-红没药醇和尿囊素的本发明的药物组合物。
进一步优选的实施方案涉及还含有吡咯烷酮羧酸锌的本发明的药物组合物。
本发明的局部用药物组合物可以呈霜剂、凝胶剂、洗剂、混悬剂、喷雾剂、软膏剂、泡沫剂的形式。
本发明的局部用药物组合物可含有以下浓度(w/w)的活性成分：
a)磷脂复合物形式的原花色素：0.01％至1％；
b)甘草次酸：0.1至5％，优选1至2％；
c)替美斯丁：0.01％至1％；和
-载体(角鲨烯、烛果油、棕榈酸辛酯和月见草油)：10-50％；
-抗氧化剂(生育酚醋酸酯0.5-5％；棕榈酸抗坏血酸酯0.01-0.1％)；
-水杨酸0.1-5％；
-透明质酸0.1-10％；
-α-红没药醇0.1-3％；
-吡咯烷酮羧酸锌0.01-1％；
-尿囊素0.1-2％。
日剂量将由医生确定；例如，其将由一或多次的每日应用、甚至更多次数的应用组成。
以下显示了根据本发明的制剂的一些实施例。
实施例1
                        霜剂
来自葡萄的原花色素和磷脂的复合物 0.100
甘草次酸 0.800
替美斯丁 0.100
棕榈酸辛酯 7.000
戊二醇 5.000
烛果油 4.000
二十烷醇、二十二醇、C12-20烷基葡糖苷 4.000
甘油硬脂酸酯和甘油(100)OE硬脂酸酯 3.000
月见草油 2.000
辛酰基甘氨酸(capryloyl glycine) 1.500
红没药醇 1.200
维生素E醋酸酯 1.000
卡波姆 0.700
辛基甘油(octyl glycerin) 0.600
水杨酸 0.500
羟甲辛吡酮 0.500
氢氧化钠 0.387
尿囊素 0.350
吡咯烷酮羧酸锌 0.100
EDTA二钠盐 0.08
棕榈酸抗坏血酸酯 0.05
没食子酸丙酯 0.02
水 65.013
总计 100.000
实施例2
                        霜剂
来自葡萄的原花色素和磷脂的复合物 0.100
甘草次酸 0.800
替美斯丁 0.100
棕榈酸辛酯 7.000
戊二醇 5.000
烛果油 4.000
二十烷醇、二十二醇、C12-20烷基葡糖苷 4.000
甘油硬脂酸酯和甘油(100)OE硬脂酸酯 3.000
角鲨烯 2.000
月见草油 2.000
辛酰基甘氨酸 1.500
红没药醇 1.200
维生素E醋酸酯 1.000
卡波姆 0.700
辛基甘油 0.600
氢氧化钠 0.387
吡咯烷酮羧酸锌 0.100
EDTA二钠盐 0.08
棕榈酸抗坏血酸酯 0.05
没食子酸丙酯 0.02
水 66.013
总计 100.000
实施例3
                        霜剂
来自葡萄的原花色素和磷脂的复合物  0.100
甘草次酸  0.800
替美斯丁  0.010
Dub po  7.000
Hydrolite-5  5.000
烛果油  4.000
Montanov 202  4.000
Arlacel 165  3.000
Squalene ex  2.000
月见草油  2.000
Lipacide C8G  1.500
红没药醇  1.200
维生素E醋酸酯  1.000
Carbopol ultrez 10  0.700
Sensiva SC 50  0.600
羟甲辛吡酮  0.500
氢氧化钠滴剂P.P.A  0.387
尿囊素 0.350
1，3-羟甲基-5，5-二甲基乙内酰脲(Nipaguard DMDMH) 0.300
吡咯烷酮羧酸锌(Zincidone) 0.100
EDTA二钠盐 0.080
棕榈酸抗坏血酸酯 0.050
没食子酸丙酯 0.020
水 65.303
总计 100.000
实施例4                            霜剂
来自葡萄的原花色素和磷脂的复合物  0.100
甘草次酸  0.800
替美斯丁  0.010
Dub po  7.000
Hydrolite-5  5.000
烛果油  4.000
Montanov 202  4.000
Arlacel 165  3.000
Squalene ex  2.000
月见草油  2.000
Lipacide C8G  1.500
红没药醇  1.200
维生素E醋酸酯  1.000
Carbopol ultrez 10  0.700
Sensiva SC 50  0.600
水杨酸  0.500
羟甲辛吡酮  0.500
氢氧化钠滴剂P.P.A  0.465
尿囊素  0.350
1，3-羟甲基-5，5-二甲基乙内酰脲(Nipaguard DMDMH)  0.300
吡咯烷酮羧酸锌(Zincidone)  0.100
EDTA二钠盐  0.080
棕榈酸抗坏血酸酯  0.050
没食子酸丙酯  0.020
水  64.725
总计  100.000
实施例5
                            霜剂
来自葡萄的原花色素和磷脂的复合物 0.100
甘草次酸 0.800
替美斯丁 0.010
Dub po 7.000
Hydrolite-5 5.000
烛果油 4.000
Montanov 202 4.000
Arlacel 165 3.000
角鲨烯 2.000
月见草油 2.000
Lipacide C8G 1.500
红没药醇 1.200
维生素E醋酸酯 1.000
Carbopol ultrez 10 0.700
Sensiva SC 50 0.600
羟甲辛吡酮 0.500
氢氧化钠滴剂P.P.A 0.387
尿囊素 0.350
1，3-羟甲基-5，5-二甲基乙内酰脲(Nipaguard DMDMH) 0.300
吡咯烷酮羧酸锌(Zincidone) 0.100
EDTA二钠盐 0.080
棕榈酸抗坏血酸酯 0.050
透明质酸钠盐 0.030
没食子酸丙酯 0.020
水 65.273
总计 100.000
实施例6
                        霜剂
来自葡萄的原花色素和磷脂的复合物 0.100
甘草次酸 2.000
替美斯丁 0.010
棕榈酸乙基己酯 9.000
牛油果 6.000
戊二醇 5.000
丁二醇 3.000
PEG-100硬脂酸酯 1.500
甘油硬脂酸酯 1.500
辛酰基甘氨酸 1.500
二十烷基葡糖苷 1.360
二十烷醇 1.320
二十二醇 1.320
红没药醇 1.200
生育酚醋酸酯 1.000
卡波姆 0.700
乙基己基甘油 0.600
羟吡酮 0.500
氢氧化钠 0.387
尿囊素 0.350
DMDM乙内酰脲 0.300
透明质酸钠 0.200
EDTA二钠 0.080
四己基癸基抗坏血酸(tetrahexyldecyl ascorbate) 0.050
没食子酸丙酯 0.020
水 61.003
总计 100.000
实施例7
                        霜剂
来自葡萄的原花色素和磷脂的复合物 0.100
甘草次酸 2.000
替美斯丁 0.010
棕榈酸乙基己酯 9.000
牛油果 6.000
戊二醇 5.000
丁二醇 3.000
PEG-100硬脂酸酯 1.500
甘油硬脂酸酯 1.500
辛酰基甘氨酸 1.500
二十烷基葡糖苷 1.360
二十烷醇 1.320
二十二醇 1.320
红没药醇 1.200
水杨酸 1.000
生育酚醋酸酯 1.000
氢氧化钠 0.785
卡波姆 0.700
乙基己基甘油 0.600
羟吡酮 0.500
尿囊素 0.350
DMDM乙内酰脲 0.300
EDTA二钠 0.080
四己基癸基抗坏血酸 0.050
没食子酸丙酯 0.020
水 59.805
总计 100.000
实施例8
                        霜剂
来自葡萄的原花色素和磷脂的复合物 0.100
甘草次酸 2.000
替美斯丁 0.010
棕榈酸乙基己酯 9.000
牛油果 6.000
戊二醇 5.000
丁二醇 3.000
PEG-100硬脂酸酯 1.500
甘油硬脂酸酯 1.500
辛酰基甘氨酸 1.500
二十烷基葡糖苷 1.360
二十烷醇 1.320
二十二醇 1.320
红没药醇 1.200
生育酚醋酸酯 1.000
卡波姆 0.700
乙基己基甘油 0.600
羟吡酮 0.500
氢氧化钠 0.387
尿囊素 0.350
DMDM乙内酰脲 0.300
透明质酸钠 0.100
EDTA二钠 0.080
四己基癸基抗坏血酸 0.050
没食子酸丙酯 0.020
水 61.103
总计 100.000
本发明的组合物显示出非常好的耐受性。它们不含有变应原性物质、动物来源的衍生物(如羊毛脂、蜂蜡、动物脂肪)、防腐剂(如对羟基苯甲酸酯类、异噻唑啉酮(isothiazolone)、酚衍生物等)，这些物质通常是造成变应性接触性皮炎的原因。
因此，由于以上提及的特征，本发明的组合物可用于治疗已经存在的皮肤变应性反应，用于防止复发形式，并且作为治疗慢性疾病如特应性皮炎、变应性接触性皮炎、脂溢性皮炎、放射性皮炎、干燥病和异位性皮炎的佐剂。
更具体地，本发明的组合物可用于治疗如刺激性和湿疹性皮炎等病症，作为敏感、脆弱皮肤的保湿剂和润泽剂；用于由药物、洗涤剂、溶剂导致的变应性刺激；用于过度暴露于日光照射导致的红斑；用于昆虫叮咬、各种原因的充血、削刮后的刺激、轻微灼伤、皮肤超反应性；作为美容治疗如用羟基乙酸或激光治疗脱皮后的平衡剂。
本发明组合物的优异的耐受性使得它们也适用于儿科。
本发明还涉及原花色素在制备局部用药物中的用途，所述药物用于治疗皮肤炎症，尤其是特应性皮炎、变应性接触性皮炎、脂溢性皮炎、放射性皮炎、干燥病、银屑病和异位性皮炎，以及治疗粘膜炎性病症，尤其是阴道、直肠、眼、齿龈和口腔粘膜的炎性病症。

Claims (25)

1.原花色素在制备用于治疗皮肤和粘膜的炎性病症的局部用药物中的用途。
2.权利要求1所述的用途，用于治疗特应性皮炎、变应性接触性皮炎、脂溢性皮炎、放射性皮炎、干燥病、银屑病和异位性皮炎。
3.权利要求1所述的用途，用于治疗阴道、直肠、口腔和眼粘膜的炎性病症。
4.权利要求1-3任一项所述的用途，其中原花色素呈磷脂复合物形式。
5.权利要求1-4任一项所述的用途，其中原花色素与甘草次酸组合。
6.权利要求1-5任一项所述的用途，其中原花色素还与替美斯丁组合。
7.权利要求1-6任一项所述的用途，其中原花色素还与α-红没药醇组合。
8.权利要求1-7任一项所述的用途，其中原花色素还与羟吡酮组合。
9.权利要求1-8任一项所述的用途，其中原花色素还与润湿剂和保湿剂组合。
10.用于局部施用的药物组合物，其包含作为活性成分的原花色素、甘草次酸和替美斯丁与适宜的载体的混合物。
11.权利要求10所述的药物组合物，其呈霜剂、凝胶剂、洗剂、混悬剂、喷雾剂、软膏剂、泡沫剂的形式。
12.权利要求10或11所述的药物组合物，其中的载体包括角鲨烯、脂肪酸、脂肪酸酯、植物油、天然或合成甘油三酯。
13.权利要求12所述的药物组合物，其中的载体包括角鲨烯、烛果油、棕榈酸辛酯和月见草油。
14.权利要求10-13任一项所述的药物组合物，还包含生育酚、抗坏血酸或其酯。
15.权利要求14所述的药物组合物，包含生育酚醋酸酯和棕榈酸抗坏血酸酯或四棕榈酸抗坏血酸酯。
16.权利要求10-15任一项所述的药物组合物，其包含水杨酸。
17.权利要求10-16任一项所述的药物组合物，其包含透明质酸。
18.权利要求10-17任一项所述的药物组合物，其还包含至少一种选自α-红没药醇、吡咯烷酮羧酸锌、尿囊素、羟吡酮的化合物。
19.权利要求10-18任一项所述的药物组合物，其中活性成分的浓度如下：
(a)磷脂复合物形式的原花色素：0.01％至1％；
(b)甘草次酸：0.1％至5％；
(c)替美斯丁：0.01％至1％。
20.权利要求19所述的组合物，其中甘草次酸的浓度为1％至2％。
21.治疗受皮肤和粘膜炎性病症影响的患者的方法，其包括局部施用有效量的原花色素。
22.权利要求21所述的方法，用于治疗特应性皮炎、变应性接触性皮炎、脂溢性皮炎、放射性皮炎、干燥病、银屑病和异位性皮炎。
23.权利要求21或22所述的方法，其还包括局部施用替美斯丁。
24.权利要求21、22或23所述的方法，其还包括局部施用甘草次酸。
25.权利要求21-24任一项所述的方法，其还包括局部施用一种或多种选自水杨酸、尿囊素、透明质酸、吡咯烷酮羧酸锌、α-红没药醇、羟吡酮的活性剂。
CN038078589A 2002-04-09 2003-03-31 包含原花色素、用于治疗皮炎的局部用药物组合物 Expired - Fee Related CN1646151B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2002A000756 2002-04-09
IT2002MI000756A ITMI20020756A1 (it) 2002-04-09 2002-04-09 Composizioni farmaceutiche topiche per il trattamento delle dermatiti
PCT/EP2003/003329 WO2003084553A1 (en) 2002-04-09 2003-03-31 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis

Publications (2)

Publication Number Publication Date
CN1646151A true CN1646151A (zh) 2005-07-27
CN1646151B CN1646151B (zh) 2010-05-05

Family

ID=11449673

Family Applications (1)

Application Number Title Priority Date Filing Date
CN038078589A Expired - Fee Related CN1646151B (zh) 2002-04-09 2003-03-31 包含原花色素、用于治疗皮炎的局部用药物组合物

Country Status (31)

Country Link
US (4) US7262180B2 (zh)
EP (1) EP1494692B1 (zh)
JP (1) JP4861606B2 (zh)
KR (1) KR101065645B1 (zh)
CN (1) CN1646151B (zh)
AR (1) AR039269A1 (zh)
AT (1) ATE361084T1 (zh)
AU (1) AU2003226754B2 (zh)
BR (2) BR0309061A (zh)
CA (1) CA2481770C (zh)
CY (1) CY1106628T1 (zh)
DE (1) DE60313597T2 (zh)
DK (1) DK1494692T3 (zh)
ES (1) ES2285158T3 (zh)
GE (1) GEP20074176B (zh)
HK (1) HK1075617A1 (zh)
HR (1) HRP20040917B1 (zh)
IL (1) IL164434A (zh)
IT (1) ITMI20020756A1 (zh)
JO (1) JO2448B1 (zh)
MX (1) MXPA04009755A (zh)
MY (1) MY137060A (zh)
NO (1) NO332753B1 (zh)
NZ (1) NZ535813A (zh)
PL (1) PL204953B1 (zh)
PT (1) PT1494692E (zh)
RU (1) RU2320362C2 (zh)
TW (1) TWI345979B (zh)
UA (1) UA81408C2 (zh)
WO (1) WO2003084553A1 (zh)
ZA (1) ZA200408100B (zh)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102206242A (zh) * 2011-03-28 2011-10-05 中国人民解放军军事医学科学院放射与辐射医学研究所 β体甘草酸及其衍生物在辐射防护中的用途
CN102614213A (zh) * 2012-02-23 2012-08-01 武汉华纳联合药业有限公司 甘草酸、甘草次酸或其盐的用途及其凝胶组合物和制备方法
CN101496772B (zh) * 2008-01-31 2013-04-24 姜宁 植物有效成分抗衰舒敏组合物
CN103356438A (zh) * 2013-07-11 2013-10-23 深圳市宜丽环保科技有限公司 一种专用于女性私处的护理液
CN103830303A (zh) * 2014-03-11 2014-06-04 北京德默高科医药技术有限公司 一种预防褥疮的组合物
CN103908458A (zh) * 2013-01-04 2014-07-09 厦门鹭佳生物科技有限公司 甘草次酸、甘草酸在制备预防或治疗放射性软组织损伤药物中的应用
CN104602697A (zh) * 2012-09-05 2015-05-06 普索莱尔西斯克利姆瑞典公司 用于治疗银屑病的组合物
CN105456047A (zh) * 2011-09-28 2016-04-06 狮王株式会社 口腔用组合物
CN114340613A (zh) * 2019-07-30 2022-04-12 德茉菲护肤有限公司 治疗特应性皮炎的组合物

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20020756A1 (it) * 2002-04-09 2003-10-09 Sinclair Pharma S R L Composizioni farmaceutiche topiche per il trattamento delle dermatiti
US20050031571A1 (en) * 2003-05-16 2005-02-10 Khaiat Alain V. Topical treatment of ingrown hairs
WO2004103321A2 (en) 2003-05-16 2004-12-02 Johnson & Johnson Consumer Companies, Inc. Topical treatment of ingrown hairs
GB0321996D0 (en) * 2003-09-19 2003-10-22 Novartis Nutrition Ag Organic compounds
ITMI20031941A1 (it) 2003-10-09 2005-04-10 Sinclair Pharmaceuticals Ltd Composizioni farmaceutiche topiche per il trattamento delle dermatiti
US20050260152A1 (en) * 2004-05-03 2005-11-24 Jaghab Khalil C Hair growth composition
JP2006022090A (ja) * 2004-06-08 2006-01-26 Ajinomoto Co Inc ピロリドンカルボン酸亜鉛塩から成る炎症抑制剤
FR2871060B1 (fr) * 2004-06-08 2008-07-11 Ajinomoto Kk Agent suppresseur pour l'inflammation et procede l'utilisant
TW200744658A (en) * 2005-10-12 2007-12-16 Pentapharm Ag Topical composition for use as a skin lightener
US7897800B2 (en) * 2006-02-03 2011-03-01 Jr Chem, Llc Chemical compositions and methods of making them
US20080103103A1 (en) * 2006-10-30 2008-05-01 Bahram Memarzadeh Reagents and methods to treat ocular diseases and infection
JP5125122B2 (ja) * 2007-01-31 2013-01-23 大正製薬株式会社 アダパレン含有外用剤組成物
KR100823533B1 (ko) * 2007-02-27 2008-04-30 바이오스펙트럼 주식회사 알파 비사볼올을 유효성분으로 포함하는 피부 상태 개선용조성물
JP4990352B2 (ja) * 2007-03-01 2012-08-01 株式会社Ｔｋバイオ研究所 アレルギー疾患及び自己免疫疾患に有効な医薬
DE102007017851A1 (de) 2007-04-16 2008-10-23 Schülke & Mayr GmbH Zusammensetzung auf Basis von Glycerinether/Polyol-Gemischen
US20100323983A1 (en) * 2007-05-11 2010-12-23 Marc Moutet Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof, and uses thereof
US20100323985A1 (en) * 2007-05-11 2010-12-23 Marc Moutet Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
WO2008139124A2 (fr) * 2007-05-11 2008-11-20 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
EP2155149A2 (fr) * 2007-05-11 2010-02-24 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
KR100823535B1 (ko) * 2008-02-20 2008-04-21 바이오스펙트럼 주식회사 알파 비사볼올을 유효성분으로 포함하는 탈모 방지 또는발모 촉진용 조성물
US20100249060A1 (en) * 2009-02-23 2010-09-30 Smith Jan G Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes
IT1397246B1 (it) * 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica
US8372382B2 (en) * 2010-10-01 2013-02-12 Mary Kay, Inc. Skin moisturizer and age fighting formula
JP5740666B2 (ja) * 2011-02-10 2015-06-24 株式会社メニコンネクト 眼科用組成物
KR20140089340A (ko) * 2011-08-16 2014-07-14 케이트 소머빌 스킨케어, 엘엘씨 피부 회춘 조성물 및 방법
ITMO20120036A1 (it) * 2012-02-15 2013-08-16 Drex Pharma S R L Composizione coadiuvante per uso topico
EP2829264B1 (en) * 2012-03-22 2018-02-14 FUJIFILM Corporation Highly transparent emulsion composition and highly transparent cosmetic
TW201412323A (zh) * 2012-06-17 2014-04-01 Kamedis Ltd 用於治療慢性發炎皮膚病之局部用組成物
BR102012022291B8 (pt) * 2012-09-04 2022-03-15 Antonio Jose Trassi Processo de fabricação de produto para tratamento da psoríase
US9861645B2 (en) * 2012-12-28 2018-01-09 Rak Holdings Llc Anti-itch scalp treatment compositions and combinations
ES2662854T3 (es) * 2013-08-19 2018-04-10 Rachid Ennamany Composición dermatológica a partir de células madre vegetales y un derivado de ácido salicílico
EP2907513A1 (en) 2014-02-18 2015-08-19 Bionoox Suisse SA Compositions comprising dihydroquercetin for use in methods for alleviating the effects associated with skin inflammatory disorders
US11077087B2 (en) 2015-03-18 2021-08-03 Bionoox Suisse Sa Compositions comprising dihydroquercetin for use in methods for treating herpes
JP6606370B2 (ja) * 2015-07-30 2019-11-13 章博 田井 抗アレルギー剤及びメディエーター遊離阻害剤
JP2018527401A (ja) * 2015-09-17 2018-09-20 ジューン ジェイコブス ラボラトリーズ， エルエルシー 放射線皮膚炎の処置および予防のための組成物および方法
WO2017214497A1 (en) 2016-06-10 2017-12-14 Clarity Cosmetics Inc. Non-comedogenic hair and scalp care formulations and method for use
KR101839109B1 (ko) * 2016-09-22 2018-03-15 ㈜프론트바이오 퍼플콘 추출물을 함유하는 피부 질환의 예방 또는 치료용 약제학적 조성물
US20190321395A1 (en) * 2018-04-20 2019-10-24 Oread Therapeutics Treatment of psoriasis, seborrheic dermatitis, and eczema of the head and neck
WO2021074718A1 (pt) * 2019-10-16 2021-04-22 Tripod Maria Creme para tratamento de acne e melasma
IT202000004069A1 (it) * 2020-02-27 2021-08-27 Ricerfarma Srl Composizioni topiche per il mantenimento e/o ripristino dell’integrità delle mucose e dell’epidermide lesa

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US487774A (en) * 1892-12-13 Sectional steam-boiler
FR2509988B1 (fr) * 1981-07-23 1986-05-30 Oreal Melange d'huiles vegetales a base d'huile de jojoba comme agent de stabilisation a l'oxydation et compositions cosmetiques le contenant
IL64700A0 (en) * 1982-01-01 1982-03-31 Binderman Itzhak Dental care compositions
JPS60109519A (ja) * 1983-11-17 1985-06-15 Nippon Shinyaku Co Ltd ニフェジピン坐剤
US4698360B1 (en) * 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
US5422118A (en) * 1986-11-07 1995-06-06 Pure Pac, Inc. Transdermal administration of amines with minimal irritation and high transdermal flux rate
IT1201151B (it) * 1987-01-14 1989-01-27 Indena Spa Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono
IT1215469B (it) 1987-05-08 1990-02-14 Yason Srl Composto ad attivita'mucoregolatrice e elastasi-inibitrice per la terapia dell'enfisema polmonare e della fibrosi polmonare.
JPH0725660B2 (ja) * 1990-05-29 1995-03-22 サンスター株式会社 日焼けに対する消炎性を有する化粧料
IT1254321B (it) * 1992-04-10 1995-09-14 Kemiprogress S R L Composizione farmaceutica per il trattamento e la prevenzione delle infiammazioni cutanee e della mucosa orale.
US5650432A (en) * 1995-03-24 1997-07-22 Jlb, Inc. Method of treating or preventing non-viral microbial infection
JPH06336421A (ja) * 1993-05-28 1994-12-06 Kose Corp 皮膚外用剤
IT1270999B (it) * 1994-07-26 1997-05-26 Indena Spa Formulazioni a base di cumarine e loro uso in campo farmaceutico e cosmetico
US5470874A (en) * 1994-10-14 1995-11-28 Lerner; Sheldon Ascorbic acid and proanthocyanidine composition for topical application to human skin
US5945409A (en) * 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
JPH1059846A (ja) * 1996-06-10 1998-03-03 Kikkoman Corp 白内障の予防または治療薬剤
US6471972B1 (en) * 1996-11-07 2002-10-29 Lvmh Recherche Cosmetic treatment method for fighting against skin ageing effects
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
WO1998052518A1 (en) * 1997-07-02 1998-11-26 Neutrogena Corporation Methods for using compositions containing dichlorophenyl imidazoldioxolan to treat seborrheic dermatitis, dandruff, psoriasis, and acne, and compositions thereof
EP0958833A1 (en) * 1998-05-20 1999-11-24 Erasmus Universiteit Rotterdam Methods and means for preventing or treating inflammation
IT1304183B1 (it) * 1998-12-18 2001-03-08 Indena Spa Complessi di proantocianidina a2 con fosfolipidi come agentiantiaterosclerotici.
JP2000212057A (ja) * 1999-01-26 2000-08-02 Kansai Koso Kk 化粧料組成物
JP2001039844A (ja) * 1999-07-29 2001-02-13 Kikkoman Corp 咽喉用うがい剤
US6274124B1 (en) * 1999-08-20 2001-08-14 Dragoco Gerberding & Co. Ag Additive for improving the water resistance of cosmetic or dermatological formulations
JP2001081021A (ja) * 1999-09-09 2001-03-27 Ichimaru Pharcos Co Ltd 化粧料組成物
US6685970B1 (en) * 1999-09-21 2004-02-03 Kyowa Hakko Kogyo Co., Ltd. Compositions containing proanthocyanidin and a vitamin B6 derivative or a salt thereof
EP1226809B1 (en) * 1999-10-29 2007-05-30 Kyowa Hakko Kogyo Co., Ltd. Skin texture-improving agents
DE10131641A1 (de) * 2000-12-22 2002-06-27 Schwabe Willmar Gmbh & Co Verbesserter und stabiler Extrakt aus Hypericum perforatum L., Verfahren zu seiner Herstellung und Verwendung als topisches Arzneimittel
EP1256335A1 (de) * 2001-05-10 2002-11-13 Cognis France S.A. Verwendung von oligomeren Procyanolidinen
ITMI20020756A1 (it) * 2002-04-09 2003-10-09 Sinclair Pharma S R L Composizioni farmaceutiche topiche per il trattamento delle dermatiti

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101496772B (zh) * 2008-01-31 2013-04-24 姜宁 植物有效成分抗衰舒敏组合物
CN102206242A (zh) * 2011-03-28 2011-10-05 中国人民解放军军事医学科学院放射与辐射医学研究所 β体甘草酸及其衍生物在辐射防护中的用途
CN105456047A (zh) * 2011-09-28 2016-04-06 狮王株式会社 口腔用组合物
CN105456047B (zh) * 2011-09-28 2018-08-07 狮王株式会社 口腔用组合物
CN102614213A (zh) * 2012-02-23 2012-08-01 武汉华纳联合药业有限公司 甘草酸、甘草次酸或其盐的用途及其凝胶组合物和制备方法
CN104602697A (zh) * 2012-09-05 2015-05-06 普索莱尔西斯克利姆瑞典公司 用于治疗银屑病的组合物
CN103908458A (zh) * 2013-01-04 2014-07-09 厦门鹭佳生物科技有限公司 甘草次酸、甘草酸在制备预防或治疗放射性软组织损伤药物中的应用
CN103356438A (zh) * 2013-07-11 2013-10-23 深圳市宜丽环保科技有限公司 一种专用于女性私处的护理液
CN103830303A (zh) * 2014-03-11 2014-06-04 北京德默高科医药技术有限公司 一种预防褥疮的组合物
CN103830303B (zh) * 2014-03-11 2016-03-02 北京德默高科医药技术有限公司 一种预防褥疮的组合物
CN114340613A (zh) * 2019-07-30 2022-04-12 德茉菲护肤有限公司 治疗特应性皮炎的组合物

Also Published As

Publication number Publication date
US20080015155A1 (en) 2008-01-17
JO2448B1 (en) 2008-10-09
ATE361084T1 (de) 2007-05-15
IL164434A0 (en) 2005-12-18
MXPA04009755A (es) 2004-12-13
BRPI0309061B1 (pt) 2017-09-12
WO2003084553A1 (en) 2003-10-16
JP2005526822A (ja) 2005-09-08
MY137060A (en) 2008-12-31
US20080114057A1 (en) 2008-05-15
AR039269A1 (es) 2005-02-16
BR0309061A (pt) 2005-02-01
AU2003226754B2 (en) 2007-08-16
PT1494692E (pt) 2007-05-31
US7262180B2 (en) 2007-08-28
RU2004129727A (ru) 2005-06-10
CA2481770A1 (en) 2003-10-16
NO20044259L (no) 2005-01-06
PL204953B1 (pl) 2010-02-26
HRP20040917B1 (hr) 2013-03-31
HK1075617A1 (en) 2005-12-23
ITMI20020756A0 (it) 2002-04-09
US20060247183A1 (en) 2006-11-02
CA2481770C (en) 2011-10-04
EP1494692B1 (en) 2007-05-02
KR20040104561A (ko) 2004-12-10
UA81408C2 (uk) 2008-01-10
DE60313597T2 (de) 2007-09-06
HRP20040917A2 (en) 2005-02-28
ES2285158T3 (es) 2007-11-16
KR101065645B1 (ko) 2011-09-20
DE60313597D1 (de) 2007-06-14
DK1494692T3 (da) 2007-09-17
ITMI20020756A1 (it) 2003-10-09
NO332753B1 (no) 2013-01-07
GEP20074176B (en) 2007-08-10
US20050143324A1 (en) 2005-06-30
PL371853A1 (en) 2005-06-27
CY1106628T1 (el) 2012-01-25
NZ535813A (en) 2007-09-28
TWI345979B (en) 2011-08-01
AU2003226754A1 (en) 2003-10-20
EP1494692A1 (en) 2005-01-12
RU2320362C2 (ru) 2008-03-27
TW200306849A (en) 2003-12-01
ZA200408100B (en) 2006-07-26
CN1646151B (zh) 2010-05-05
IL164434A (en) 2009-09-22
JP4861606B2 (ja) 2012-01-25

Similar Documents

Publication Publication Date Title
CN1646151B (zh) 包含原花色素、用于治疗皮炎的局部用药物组合物
AU600904B2 (en) Composition for the treatment of acne
US20040214750A1 (en) Medicaments for healing skin conditions in humans
US10596205B2 (en) Topical medicament for skin and mucosal injuries
AU2002334785B2 (en) Combinatorial anti-acne compositions
US20040131702A1 (en) Use of selenite or preparation containing selenite for treating wounds
WO2020079717A1 (en) Ozonized phytotherapic composition for tissue and bone regeneration
WO2019175902A1 (en) A topical preparation for various skin ailments
Kantam et al. Aloe Vera–Nature’s Power
Larkina et al. EFFECT OF CALCIUM HYDROXYAPATITE AND HYALURONIC ACID INJECTIONS ON INFLAMMATION MARKERS OF PERIODONT TISSUE
KR20010025824A (ko) 여드름 피부용 화장료 조성물
CN116059128A (zh) 抗炎组合物
US20200281877A1 (en) Method for prevention and treatment of acne, eczema, psoriasis, and related dermatological conditions with composition comprising a sphingolipid and sulphur compounds
KR20040033945A (ko) 사포나리아 알로에 추출물을 함유하는 여드름 피부용 화장료 조성물
KR20170094609A (ko) 치주염 예방액의 제조 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075617

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1075617

Country of ref document: HK

TR01 Transfer of patent right

Effective date of registration: 20170509

Address after: Wiltshire

Patentee after: Mailer Research Ltd

Address before: surrey

Patentee before: Sinclair Pharmaceuticals Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190202

Address after: Wiltshire

Patentee after: United Pharmaceutical Co Ltd

Address before: Wiltshire

Patentee before: Mailer Research Ltd

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100505

Termination date: 20210331

CF01 Termination of patent right due to non-payment of annual fee